JAMA Psychiatry saw a post-COVID-19 pandemic period of steady growth and impact in 2023. Our editorial team worked hard to maintain high standards, stay abreast of developments in the field, and present to our audience the best psychiatric research of the year. Among many others, we published a randomized clinical trial on sequential adaptive interventions for psychosis risk, 1 an article on the adverse impact of abortion restrictions on mental health, 2 and a Viewpoint series on mental health in a changing planet. 3 We also continued to cover all aspects of the therapeutic potential and pitfalls of psychedelics and even devoted one of our popular podcasts to the topic. 4 The past year saw continued runs of years with very high submission volumes. We received more than 1800 submissions, of which 1442 were research manuscripts; 9% of research manuscripts were ultimately accepted (Table ). We also maintained our rapid turnaround times, with a median of 3 days to reach a decision for manuscripts without peer review and 33 days for peer-reviewed manuscripts. Our journal has had a well-earned reputation for a rigorous review process for decades, and the credit for maintaining our high standards goes, as always, to our expert peer reviewers. The complete list of our 2023 reviewers can be found online. 13 The Table also lists multiple other metrics characterizing JAMA Psychiatry in 2023 as a highly influential journal. The Journal Impact Factor was 25.8; we send our electronic table of contents to more than 135 000 recipients each week; and users viewed or downloaded articles from our website more than 8.8 million times. Finally, you can view in the Table our articles with the highest number of views/downloads, [5][6][7] Altmetric scores (reflecting influence in news and social media), [7][8][9] and Web of Science citations. [10][11][12] When I give presentations about JAMA Psychiatry and in my Year in Review articles, I highlight our journal's ambition to be the outlet for the best psychiatric research articles. Original Investigations are the lifeblood of our journal and will remain that way. We have always prioritized meaningful advances coming from rigorous and definitive research over flashy topics that may be popular one year and forgotten the next, even if those flashy topics might bring the journal greater attention and recognition. Thus, I ask all of you to consider JAMA Psychiatry as a venue for your best research work. On the other hand, showcasing original research does not mean excluding other kinds of articles from the journal. We are constantly striving to improve the journal beyond our core strengths, and this has meant the introduction of new features in the journal over the past decade, including the Viewpoints, Psychiatry and Neuroscience articles, JAMA Network Insights, and Brief Reports article formats and the addition of visual abstracts with published randomized clinical trials.